Amgen AMGN
- Market cap
- $252.3B
- PE
- 29.0×
- 10y median 21.2×
- Forward PE
- 19.8×
- 10y median 14.5×
- Price to sales
- 6.6×
- EV/EBIT
- 25.8×
- Revenue, 12 months
- $38.1B
- +9% on a year ago
- Net margin
- 23.0%
- Free cash flow yield
- 4.0%
Amgen trades at 29.0× trailing earnings, pricier than 80% of the last ten years. Revenue was $38.1B over the last twelve months, up 9% on a year earlier with a 23% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.9B+4% | $8.2B+20% | $7.4B+22% | $8.4B+20% | $8.5B+23% | $9.1B+11% | $8.1B+9% | $9.2B+9% | $9.6B+12% | $9.9B+9% | $8.6B+6% | $10.1B+10% | |
| Cost of revenue | $1.8B+14% | $3.1B+78% | $3.2B+86% | $3.2B+79% | $3.3B+83% | $3.1B+0% | $3B−7% | $3B−7% | $3.1B−7% | $3B−4% | $2.7B−8% | $2.8B−7% |
| Gross profit | $5.1B+1% | $5.1B−0% | $4.2B−3% | $5.2B−0% | $5.2B+2% | $6B+18% | $5.2B+22% | $6.2B+20% | $6.5B+25% | $6.9B+15% | $5.9B+13% | $7.2B+17% |
| R&D | $1.1B−3% | $1.5B+16% | $1.3B+27% | $1.4B+30% | $1.4B+34% | $1.7B+12% | $1.5B+11% | $1.7B+21% | $1.9B+31% | $2.1B+24% | $1.7B+16% | $1.9B+7% |
| SG&A | $1.4B+5% | $2.3B+45% | $1.8B+44% | $1.8B+38% | $1.6B+20% | $1.9B−17% | $1.7B−7% | $1.7B−5% | $1.7B+6% | $2B+4% | $1.6B−5% | $1.7B+3% |
| $2B−24% | $1.3B−43% | $991M−48% | $1.9B−29% | $2B+1% | $2.3B+82% | $1.2B+19% | $2.7B+39% | $2.5B+23% | $2.7B+18% | $2.7B+126% | $3.5B+32% | |
| Interest expense | $759M+106% | $821M+98% | $824M+52% | $808M+7% | $776M+2% | $747M−9% | $723M−12% | $694M−14% | $685M−12% | $653M−13% | $657M−9% | $673M−3% |
| Pre-tax income | $1.9B−19% | $852M−51% | −$68M | $794M−51% | $3.1B+59% | $782M−8% | $2B | $1.6B+98% | $3.9B+26% | $1.5B+94% | $2.1B+6% | $2.8B+77% |
| $217M−13% | $85M−36% | $45M−93% | $48M−80% | $271M+25% | $155M+82% | $243M+440% | $136M+183% | $705M+160% | $181M+17% | $265M+9% | $393M+189% | |
| Net income | $1.7B−19% | $767M−53% | −$113M | $746M−46% | $2.8B+64% | $627M−18% | $1.7B | $1.4B+92% | $3.2B+14% | $1.3B+113% | $1.8B+5% | $2.4B+66% |
| $3.22−19% | $1.42−53% | −$0.21 | $1.38−46% | $5.22+62% | $1.16−18% | $3.20 | $2.65+92% | $5.93+14% | $2.45+111% | $3.34+4% | $4.37+65% | |
| 538M+0% | 540M+0% | 536M−0% | 541M+1% | 542M+1% | 542M+0% | 541M+1% | 541M+0% | 542M+0% | 543M+0% | 544M+1% | 544M+1% |
Gross profit: 73 periods, Q2 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
EPS, diluted: Q4 FY08: quarter's net income to common over its shares, to the cent. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 11 periods, Q4 FY08 to Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days. 6 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release. Q4 FY17: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet. Figures from older filings without data tags, and from a results release before its 10-Q, are read from the document's text and checked against it.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $10.1B | $9.9B to $10.2B | $5.79 | $5.55 to $6.09 | 19 |
| Q4 FY26 | $10.3B | $10.1B to $10.5B | $5.79 | $5.24 to $6.09 | 17 |
| Q1 FY27 | $9.4B | $9.1B to $9.6B | $5.62 | $5.42 to $5.78 | 7 |
| Q2 FY27 | $10.3B | $10.1B to $10.6B | $6.41 | $6.18 to $6.60 | 15 |
| Q3 FY27 | $10.3B | $10B to $10.5B | $6.32 | $6.10 to $6.50 | 9 |
| Q4 FY27 | $10.5B | $10.2B to $10.7B | $6.28 | $6.05 to $6.45 | 7 |
| Q1 FY28 | $9.5B | $9.2B to $9.7B | $5.86 | $5.65 to $6.03 | 9 |
| Q2 FY28 | $10.3B | $10B to $10.6B | $6.68 | $6.44 to $6.87 | 8 |
Peers
Companies in Drug Manufacturers - General nearest Amgen's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMGNAmgen | $252.3B | 29.0× | 21.2× | 19.8× | 6.6× | +9% | 23.0% |
| GILDGilead Sciences | $212.5B | n/m | 18.8× | 19.8× | 6.9× | +7% | −12.5% |
| PFEPfizer | $176B | 40.6× | 15.8× | 11.2× | 2.8× | −0% | 6.8% |
| MRKMerck | $359.5B | 150× | 25.0× | 17.2× | 5.3× | +5% | 3.6% |
| BMYBristol-Myers Squibb | $128.7B | 14.0× | 19.9× | 9.8× | 2.6× | +4% | 18.5% |
| ABBVAbbVie | $511.6B | 49.8× | 27.9× | 18.3× | 7.7× | +11% | 15.7% |
| JNJJohnson & Johnson | $650.2B | 40.9× | 24.3× | 23.9× | 6.5× | +8% | n/m |
| LLYEli Lilly and | $1.3T | 46.5× | 41.6× | 30.9× | 15.6× | +46% | 31.9% |
| BIIBBiogen | $37B | 44.3× | 16.2× | 19.0× | 3.7× | +0% | 8.3% |
| Peer median | $286B | 44.3× | 22.1× | 18.7× | 5.9× | +6% | 8.3% |
More on Amgen
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 33Healthcare stocks with the highest dividend yields
- #10of 24Large drugmakers with the fastest earnings growth
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .